NRAS G12A

Clinical trials for NRAS G12A explained in plain language.

Never miss a new study

Get alerted when new NRAS G12A trials appear

Sign up with your email to follow new studies for NRAS G12A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New immunotherapy option for High-Risk pancreatic cancer patients

Disease control AVAILABLE

This expanded access program offers ELI-002 7P immunotherapy to patients with pancreatic cancer that has specific KRAS or NRAS gene mutations and who are at high risk of the cancer returning after surgery. The treatment aims to stimulate the immune system to fight any remaining c…

Matched conditions: NRAS G12A

Sponsor: Elicio Therapeutics • Aim: Disease control

Last updated May 16, 2026 23:34 UTC

NRAS G12A

Get alerted when new NRAS G12A trials appear

New immunotherapy option for High-Risk pancreatic cancer patients